Literature DB >> 30334240

When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer.

Annerleim Walton-Diaz, Soroush Rais-Bahrami.   

Abstract

Prostate cancer remains the only solid tumor diagnosed using transrectal ultrasound-guided sampling of the gland, and not an image-based, lesion-directed approach. This technique has limitations in that it underdiagnoses clinically significant disease and overdiagnoses indolent tumors resulting in overtreatment of patients. Technical advances in MRI in the last decade have made this method the preferred imaging modality for prostate anatomy and for risk assessment of prostate cancer. As of 2018, the indications for MRI in the diagnosis and risk assessment of prostate cancer have expanded from preoperative evaluation to the pre-biopsy setting, as well as for surveillance protocols. This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.

Entities:  

Mesh:

Year:  2018        PMID: 30334240

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  2 in total

1.  Consensus on Screening, Diagnosis, and Staging Tools for Prostate Cancer in Developing Countries: A Report From the First Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Authors:  Arie Carneiro; Douglas Racy; Carlos Eduardo Bacchi; Katia Ramos Moreira Leite; Renee Zon Filippi; Igor Austin Fernandes Martins; Joao Victor Salvajoli; Rodrigo de Morais Hanriot; Ronaldo Hueb Baroni; Alvaro Sadek Sarkis; Antonio Carlos Lima Pompeo; Bruno Santos Benigno; Gustavo Cardoso Guimarães; Saad Aldousari; Aguinaldo Cesar Nardi; Alexandre Saad Feres Lima Pompeo; Amr Nowier; Archimedes Nardozza; Ari Adamy; Celso Heitor de Freitas; Daher Cezar Chade; Danilo Armando Citarella Otero; Deusdedit Cortêz Vieira da Silva Neto; Eduardo Franco Carvalhal; Fernando Korkes; Robson Ferrigno
Journal:  JCO Glob Oncol       Date:  2021-04

2.  Results of the IROCA international clinical audit in prostate cancer radiotherapy at six comprehensive cancer centres.

Authors:  Carla Lopes de Castro; Magdalena Fundowicz; Alvar Roselló; Josep Jové; Letizia Deantonio; Artur Aguiar; Carla Pisani; Salvador Villà; Anna Boladeras; Ewelina Konstanty; Marta Kruszyna-Mochalska; Piotr Milecki; Diego Jurado-Bruggeman; Joana Lencart; Ignasi Modolell; Carles Muñoz-Montplet; Luisa Aliste; Maria Gloria Torras; Montserrat Puigdemont; Luísa Carvalho; Marco Krengli; Ferran Guedea; Julian Malicki
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.